Teva Unveils Promising TEV-'749 Schizophrenia Treatment Data at SIRS 2025

Teva Pharmaceuticals has shared encouraging new data on TEV-'749, a long-acting injectable (LAI) formulation of olanzapine for schizophrenia, at the 2025 Congress of the Schizophrenia International Research Society (SIRS). A survey conducted among patients, nurses, and physicians in the Phase 3 SOLARIS trial found overwhelmingly positive responses, with 92% of patients, 87% of nurses, and 72% of physicians expressing satisfaction. The study highlights the potential of TEV-'749 to improve treatment adherence and ease of use with a convenient monthly dosing schedule and subcutaneous administration, which could eliminate the need for post-injection observation due to Post-Injection Delirium/Sedation Syndrome (PDSS).

“Schizophrenia is a complex condition, and treatment adherence remains a challenge,” noted Dr. Andrew J. Cutler, Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University. “The prospect of a long-acting olanzapine formulation without PDSS risk could be a game-changer.” With nearly 30 years of clinical use, olanzapine remains a cornerstone treatment for schizophrenia, and Teva’s innovative approach with TEV-'749 aims to enhance patient experience while maintaining proven efficacy. The latest data reinforce Teva’s commitment to advancing schizophrenia care and addressing real-world treatment challenges.